Is Mobocertinib a targeted drug?

Mobocertinib (Mobocertinib) is a third-generation targeted drug designed to treat a specific type of non-small cell lung cancer (NSCLC), namely patients with EGFR (epidermal growth factor receptor) mutation-positive NSCLC. It is designed to overcome resistance issues with previous generation drugs. Mobosetinib has higher selectivity and specifically inhibits EGFR mutations, especially the EGFR T790M mutation, which is often associated with resistance to EGFR inhibitors. Therefore, moboxetinib can effectively inhibit the growth and division of tumor cells, providing a new treatment option, especially for patients who have developed resistance to early-generation drugs.